-
AJH Major Publication | Chinese Team First to Discover Prognostic Value of NK Cell Chimerism in Post-Transplant MRD-Negative Patients
Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) represents a potentially curative option for various hematologic malignancies. However, disease relapse remains the primary cause of treatment failure. Donor-derived immune cells play…
-
2025 ICML | Prof. Lu-Gui Qiu on Igemetostat’s Broad Efficacy in R/R NHL and Future Strategies
At the conference, Professor Lu-Gui Qiu from the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, presented the results of a Phase I/II clinical trial investigating…
-
2025 BOC/BOA Kicks Off on July 4! Professor Jun Ma Invites You to Explore Global Frontiers in Hematologic Malignancies and Witness a New Era of Chinese Innovation
The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC), held in conjunction with Best of ASCO 2025 China (BOC/BOA), will take place from July 4–5 in the historic city of Nanjing. This prestigious event will gather leading oncology experts from across China and around the world to reflect on major clinical oncology…
-
2025 ICML | Prof. : Insights from the EBMT Lymphoma Working Party—What’s Driving Better Transplant Outcomes?
Oncology Frontier – Hematology Frontier: Based on EBMT data, what are the core drivers behind the improved transplant outcomes for relapsed Hodgkin lymphoma in the past decade? How much of…
-
Wenyu Shi: Latest Advances in Lymphoma-Associated Hemophagocytic Lymphohistiocytosis (HLH) | 2025 Hematology Translational and Innovation Conference
As vibrant blossoms filled the streets of Shanghai and the Huangpu River shimmered beneath the morning sun, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, was convened from June 27 to 29. This prominent academic event brought together leading experts from China and abroad to share…
-
Wenbin Qian: Latest Advances in CAR-NK Cell Therapy for Lymphoma | 2025 Hematology Translational and Innovation Conference
As summer bloomed in Shanghai and the tide of the Huangpu River caught the morning light, the 2025 Hematology Translational and Innovation Conference, held in parallel with the 10th Shanghai Lymphoid Disease Symposium, took place from June 27 to 29. This major academic event welcomed prominent experts from China and abroad to share cutting-edge achievements,…
-
CAH 2025 | Professor Jin Lu: Advancing High-Quality Development in Multiple Myeloma Care through Standardized Treatment, Data Integration, and Optimized Follow-up
From June 20 to 22, the 19th Annual Meeting of the Chinese Medical Doctor Association Hematology Branch and the 2025 China Hematology Conference (CAH 2025) was held in the historic city of Xi’an. As a major academic event in China’s hematology community, the conference maintained its core mission of “serving clinical practice,” with a strong…
-
CAH 2025 | Professor Lei Fan: Advancing a Paradigm Shift in the Treatment of Indolent Lymphoma and Exploring a China-Specific Model for Lifelong Disease Management
In early summer, the historic city of Xi’an welcomed a gathering of leading experts at the 19th Annual Meeting of the Chinese Association of Hematologists and the 2025 China Annual Hematology Conference (CAH 2025), held from June 20 to 22. The event was co-hosted by the Chinese Medical Doctor Association and its Hematology Branch, in…
Connecting Medical Expertise through Media